Methods: In this prospective study, 36 patients with moderate-to-severe plaque psoriasis receiving anti-TNF-α, anti-IL-17, or anti-IL-23 therapy were assessed at baseline and after 12 weeks. The gene discussed is IL17A; the disease is psoriasis vulgaris.